Loading clinical trials...
Loading clinical trials...
OTT166-201 A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR)
Conditions
Interventions
OTT166
Vehicle control
Locations
68
United States
Clinical Site 123
Peoria, Arizona, United States
Clinical Site 150
Phoenix, Arizona, United States
Clinical Site 111
Beverly Hills, California, United States
Clinical Site 113
Encino, California, United States
Clinical Site 138
Fresno, California, United States
Clinical Site 129
Huntington Beach, California, United States
Start Date
July 29, 2022
Primary Completion Date
December 29, 2023
Completion Date
December 29, 2023
Last Updated
August 9, 2024
NCT07351786
NCT03713268
NCT03135327
NCT06782997
NCT06787482
NCT05147701
Lead Sponsor
OcuTerra Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions